Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

2.36
-0.0800-3.28%
Post-market: 2.36-0.0016-0.07%19:51 EST
Volume:204.69K
Turnover:486.49K
Market Cap:66.31M
PE:-1.00
High:2.42
Open:2.42
Low:2.35
Close:2.44
52wk High:6.01
52wk Low:1.15
Shares:28.10M
Float Shares:20.75M
Volume Ratio:0.43
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3483
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-97.83%
PB:-2.57
PE(LYR):-1.00

Loading ...

BRIEF-Nrx Pharmaceuticals Inc - Amends Ind Filing For Nrx-101 To Include Tms Use

Reuters
·
Dec 03

NRX Pharmaceuticals Inc - Amends Ind Filing for NRX-101 to Include Tms Use

THOMSON REUTERS
·
Dec 03

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 02

NRX Pharmaceuticals Inc - Gdufa Goal Date Set for July 29, 2026

THOMSON REUTERS
·
Dec 02

NRX Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of Anda for Ketafree™, a Preservative-Free Iv Ketamine

THOMSON REUTERS
·
Dec 02

NRX Pharmaceuticals Inc - Applies for Ketafree as Proprietary Product Name

THOMSON REUTERS
·
Dec 02

FDA Accepts NRx Pharmaceuticals' ANDA for KETAFREE with Review Goal Date Set

Reuters
·
Dec 02

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

GlobeNewswire
·
Dec 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS)

TIPRANKS
·
Nov 18

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs

TIPRANKS
·
Nov 18

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 17

NRX Pharmaceuticals Q3 EPS $(0.27) May Not Be Comparable To $0.18 Estimate, Sales $242.000K May Not Be Comparable To $15.000M Estimate

Benzinga
·
Nov 17

NRX Pharmaceuticals posts Q3 loss and reports first revenue after Dura Medical acquisition

Reuters
·
Nov 17

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Nov 17

NRX Pharmaceuticals Inc - Refiles Anda for Ketafree, Expects Q2 2026 Gdufa Date

THOMSON REUTERS
·
Nov 17

Press Release: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Nov 17

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

GlobeNewswire
·
Nov 12

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 11

NRx Pharmaceuticals (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida

TIPRANKS
·
Nov 11

HOPE Therapeutics Launches One-Day Depression Treatment in Florida

Reuters
·
Nov 10